CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- 4 Grant or award PRESIDENT AND CEO acquired 195,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 129,000 shares at $1.60 ($205,884)
- 3 Insider Initial Statement of Ownership
- 4/A Grant or award Sr. VP and CFO acquired 90,909 shares (grant or award)
- 4 Grant or award Sr. VP and CFO acquired 99,010 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award PRESIDENT AND CEO acquired 263,960 shares (grant or award)
- 4 Open-market buy PRESIDENT AND CEO bought 64,516 shares at an average $1.40 ($90,484)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award President and CEO acquired 800,000 shares (grant or award)
- 4 Grant or award Sr. VP and CFO acquired 201,903 shares (grant or award)
- 4 Grant or award VP, Research & Development acquired 35,115 shares (grant or award)
- 4 Grant or award Sr. VP, Operations acquired 187,344 shares (grant or award)
Page 2 of 12 · 223 filings